These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 27762096)

  • 1. Beneficial effect of lixisenatide after 76 weeks of treatment in patients with type 2 diabetes mellitus: A meta-analysis from the GetGoal programme.
    Broglio F; Mannucci E; Napoli R; Nicolucci A; Purrello F; Nikonova E; Stager W; Trevisan R
    Diabetes Obes Metab; 2017 Feb; 19(2):248-256. PubMed ID: 27762096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lixisenatide treatment improves glycaemic control in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin with or without sulfonylurea: a randomized, double-blind, placebo-controlled, 24-week trial (GetGoal-M-Asia).
    Yu Pan C; Han P; Liu X; Yan S; Feng P; Zhou Z; Lv X; Tian H; Jin Kui Y; Su B; Shang S; Niemoeller E
    Diabetes Metab Res Rev; 2014 Nov; 30(8):726-35. PubMed ID: 24639432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S).
    Rosenstock J; Hanefeld M; Shamanna P; Min KW; Boka G; Miossec P; Zhou T; Muehlen-Bartmer I; Ratner RE
    J Diabetes Complications; 2014; 28(3):386-92. PubMed ID: 24650952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P).
    Pinget M; Goldenberg R; Niemoeller E; Muehlen-Bartmer I; Guo H; Aronson R
    Diabetes Obes Metab; 2013 Nov; 15(11):1000-7. PubMed ID: 23627775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lixisenatide as add-on to oral anti-diabetic therapy: an effective treatment for glycaemic control with body weight benefits in type 2 diabetes.
    Raccah D; Gourdy P; Sagnard L; Ceriello A
    Diabetes Metab Res Rev; 2014 Nov; 30(8):742-8. PubMed ID: 24687427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of lixisenatide in a predominantly Asian population with type 2 diabetes insufficiently controlled with basal insulin: The GetGoal-L-C randomized trial.
    Yang W; Min K; Zhou Z; Li L; Xu X; Zhu D; Venkateshwar Rao A; Murthy LS; Zhang N; Li I; Niemoeller E; Shang S
    Diabetes Obes Metab; 2018 Feb; 20(2):335-343. PubMed ID: 28742225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pronounced reduction of postprandial glucagon by lixisenatide: a meta-analysis of randomized clinical trials.
    Ahrén B; Gautier JF; Berria R; Stager W; Aronson R; Bailey CJ
    Diabetes Obes Metab; 2014 Sep; 16(9):861-8. PubMed ID: 24641271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia).
    Seino Y; Min KW; Niemoeller E; Takami A;
    Diabetes Obes Metab; 2012 Oct; 14(10):910-7. PubMed ID: 22564709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lixisenatide, a novel GLP-1 receptor agonist: efficacy, safety and clinical implications for type 2 diabetes mellitus.
    Bolli GB; Owens DR
    Diabetes Obes Metab; 2014 Jul; 16(7):588-601. PubMed ID: 24373190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial.
    Rosenstock J; Guerci B; Hanefeld M; Gentile S; Aronson R; Tinahones FJ; Roy-Duval C; Souhami E; Wardecki M; Ye J; Perfetti R; Heller S;
    Diabetes Care; 2016 Aug; 39(8):1318-28. PubMed ID: 27222510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M).
    Ahrén B; Leguizamo Dimas A; Miossec P; Saubadu S; Aronson R
    Diabetes Care; 2013 Sep; 36(9):2543-50. PubMed ID: 23536584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1).
    Riddle MC; Forst T; Aronson R; Sauque-Reyna L; Souhami E; Silvestre L; Ping L; Rosenstock J
    Diabetes Care; 2013 Sep; 36(9):2497-503. PubMed ID: 23564915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Lixisenatide in Japanese Patients with Type 2 Diabetes Insufficiently Controlled with Basal Insulin±Sulfonylurea: A Subanalysis of the GetGoal-L-Asia Study.
    Seino Y; Ikeda Y; Niemoeller E; Watanabe D; Takagi H; Yabe D; Inagaki N
    Horm Metab Res; 2015 Nov; 47(12):895-900. PubMed ID: 26039935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of once-daily glucagon-like peptide-1 receptor agonist lixisenatide as an add-on treatment to basal insulin in Asian and white adults with type 2 diabetes mellitus: An individual-level pooled analysis of phase III studies.
    Liu F; Liu Y; Liu M; Wu G; Zhang M; Zhang X; Cui N; Yin H; Chen L
    J Diabetes Investig; 2021 Aug; 12(8):1386-1394. PubMed ID: 33475222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Indirect comparison of lixisenatide versus neutral protamine Hagedorn insulin as add-on to metformin and sulphonylurea in patients with type 2 diabetes mellitus.
    Fournier M; Germe M; Theobald K; Scholz GH; Lehmacher W
    Ger Med Sci; 2014; 12():Doc14. PubMed ID: 25332702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L).
    Riddle MC; Aronson R; Home P; Marre M; Niemoeller E; Miossec P; Ping L; Ye J; Rosenstock J
    Diabetes Care; 2013 Sep; 36(9):2489-96. PubMed ID: 23628617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Lixisenatide and Insulin Glargine, Versus Insulin Glargine in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy: The LixiLan Proof-of-Concept Randomized Trial.
    Rosenstock J; Diamant M; Aroda VR; Silvestre L; Souhami E; Zhou T; Perfetti R; Fonseca V;
    Diabetes Care; 2016 Sep; 39(9):1579-86. PubMed ID: 27284114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lixisenatide treatment for older patients with type 2 diabetes mellitus uncontrolled on oral antidiabetics: meta-analysis of five randomized controlled trials.
    Hanefeld M; Berria R; Lin J; Aronson R; Darmon P; Evans M; Van Gaal L
    Adv Ther; 2014 Aug; 31(8):861-72. PubMed ID: 25143188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial.
    Ratner RE; Rosenstock J; Boka G;
    Diabet Med; 2010 Sep; 27(9):1024-32. PubMed ID: 20722676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of lixisenatide once daily vs. placebo in people with Type 2 diabetes insufficiently controlled on metformin (GetGoal-F1).
    Bolli GB; Munteanu M; Dotsenko S; Niemoeller E; Boka G; Wu Y; Hanefeld M
    Diabet Med; 2014 Feb; 31(2):176-84. PubMed ID: 24117597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.